Core Insights - Perrigo Company plc is identified as one of the most oversold healthcare stocks in 2025, focusing on high-growth, high-margin categories in North America and Europe [2] Financial Performance - In Q2 2025, Perrigo reported net sales of $1.06 billion, reflecting a 0.9% decline year-over-year due to divestitures and exited products, particularly in infant formula and digestive health [3] - The company is experiencing soft seasonal demand in allergy, sun care, and blister care categories, along with a slower-than-expected recovery in infant formula [3] Strategic Initiatives - Perrigo is implementing a "Three-S" strategy—Stabilize, Streamline, and Strengthen—by divesting non-core assets, including the Dermacosmetics business, which is expected to close in Q1 2026 [4] - This strategy aims to streamline operations, reinforce the balance sheet, accelerate debt reduction, and enable a greater focus on its core self-care portfolio [4] Operational Enhancements - The company is enhancing operations through a global operating model upgrade and strengthened brand-building capabilities, contributing to market share gains in key segments [5] - Perrigo is emphasizing innovation and expansion in pain and sleep aids, nutrition, and upper respiratory products, aligning resources with higher-growth categories [5]